Author

I. Sokirniy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. G. Volk· 1 shared A. Shah· 1 shared A. strikoudis· 1 shared B. Accordi· 1 shared B. Bornhauser· 1 shared B. T. Gutierrez Diaz· 1 shared B. Ueberheide· 1 shared C. A. Martinez· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. G. Volk

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genomic and experimental evidence that alternate transcription initiation of the Anaplastic Lymphoma Kinase (ALK) kinase domain does not predict single agent sensitivity to ALK inhibitors.

H. Inam, I. Sokirniy, Y. Rao, A. Shah, F. Naeemikia, E. O'Brien, C. Dong, D. M. McCandlish, J. R. Pritchard

The paper reanalyzes ALKATI's role in melanoma using genomic and experimental methods, finding it does not predict single-agent ALK inhibitor sensitivity.

bioRxiv · Jun 17, 2021 · PreprintBioengineering

USP7 cooperates with NOTCH1 to drive the oncogenic transcriptionalprogram in T cell leukemia

P. Ntziachristos, K. Arcipowski, Q. Jin, C. A. Martinez, Y. Zhu, B. T. Gutierrez Diaz, K. Wang, M. Johnson, A. G. Volk, F. Wang, J. wu, H. Wang, I. Sokirniy, P. Thomas, Y. A. Goo, , J. D Crispino

This study identifies USP7 as a key driver of T-cell leukemia by stabilizing NOTCH1 and JMJD3, showing USP7 inhibition blocks leukemia growth and suggests it as a therapeutic target.

bioRxiv · Jan 16, 2018Cancer Biology